Tharimmune, Inc.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell THAR and other ETFs, options, and stocks.

About THAR

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. 

CEO
Sireesh Appajosyula
CEOSireesh Appajosyula
Employees
2
Employees2
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
2017
Founded2017
Employees
2
Employees2

THAR Key Statistics

Market cap
7.46M
Market cap7.46M
Price-Earnings ratio
-0.23
Price-Earnings ratio-0.23
Dividend yield
Dividend yield
Average volume
51.49K
Average volume51.49K
High today
$1.85
High today$1.85
Low today
$1.70
Low today$1.70
Open price
$1.70
Open price$1.70
Volume
9.30K
Volume9.30K
52 Week high
$6.39
52 Week high$6.39
52 Week low
$0.952
52 Week low$0.952

People also own

Based on the portfolios of people who own THAR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.